Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The ability of macrophages to integrate metabolic and immune signaling is a key determinant of atherogenesis. Sallam et al. (p 304) report the identification of a non-coding RNAs, MeXis, that coordinates cellular responses to cholesterol overload in macrophages and lesion development. The cover image is a scanning electron micrograph depicting a dying cholesterol-loaded macrophage with cholesterol crystals piercing the cell and extending from the cell surface. Image Credit: Thomas Weston, Cuiwen He and Stephen G Young, UCLA.
Therapies for Alzheimer's disease and other neurodegenerative diseases are desperately needed. Yet, a string of disappointments in the neurodegenerative therapy space has meant that several companies over the years have ended their investment in the field. Some companies have diversified their research and development (R&D) models to hedge their bets. Maintaining this diversity to bring down the silos between big pharma and smaller research teams may be necessary to jumpstart and sustain progress in combatting neurodegenerative conditions.
Studies in metastatic melanoma, non-small-cell lung carcinoma and renal cell carcinoma indicate certain bacteria within the gut microbiota enhance clinical responses to checkpoint blockade.
In a nonhuman primate model of Zika virus infection, structural and cellular pathology deficits that could have a long-lasting impact on neural development and neurocognitive function are detected in offspring of infected mothers.
An active immunosuppressive pathway is identified in colon cancer that confers immune evasion by the cancer and can be targeted to synergize with immunotherapies.
A large proportion of basal cell carcinomas develop resistance independently of the canonical mutations in genes encoding hedgehog pathway components. An unbiased analysis investigating alternative pathways of resistance uncovers the role of cytoskeletal signaling in driving noncanonical activation of hedgehog signaling through nuclear translocation of SRF and MKL1. These results advance understanding of the mechanisms underlying drug resistance and provide new actionable insights for clinical translation.
Combining the kinase inhibitor sorafenib with allogeneic stem cell transplantation boosts immune responses against a subtype of acute myelogenous leukemia, suggesting potential clinical benefit.
The conserved long noncoding RNA MeXis has anti-atherosclerotic effects in mice by acting with the nuclear hormone receptor LXR in macrophages to promote cholesterol efflux.
Optimal T cell activation requires signaling through the T cell receptor (signal 1), a co-stimulatory receptor (signal 2) and a cytokine receptor (signal 3), yet most chimeric antigen receptors (CARs) lack a domain to transduce signal 3. Kagoya et al. now report their development of a new CAR that incorporates a JAK–STAT cytokine signaling domain and mediates potent antitumor effects.
A small-molecule antagonist of PPAR-γ expands human cord blood HSPCs via downregulation of fructose 1,6-bisphosphatase expression, thereby enhancing glycolysis.